This is a Phase 1, open-label, first-in-human, dose-escalation and expansion study of CHS-114, a monoclonal antibody that targets CCR8, as a monotherapy in patients with solid tumors.
Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma
This is a Phase 1, open-label, first-in-human, dose-escalation and expansion study of CHS-114, a monoclonal antibody that targets CCR8, as a monotherapy in patients with solid tumors.
Study of CHS-114 in Participants With Advanced Solid Tumors
-
Stanford Cancer Center, Palo Alto, California, United States, 94305
SCRI Lake Nona DDU (FL Cancer Specialists), Orlando, Florida, United States, 32827
Emory Winship Cancer Institute, Atlanta, Georgia, United States, 30308
University of Louisville, Louisville, Kentucky, United States, 40202
University of Michigan, Ann Arbor, Michigan, United States, 48104
Barbara Ann Karmanos Cancer Institute - Karmanos Cancer Center, Detroit, Michigan, United States, 48201
Washington University, Saint Louis, Missouri, United States, 63110
University of Cincinnati, Cincinnati, Ohio, United States, 45219
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States, 37203
START- San Antonio, San Antonio, Texas, United States, 78229
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
Yes
Coherus Biosciences, Inc.,
Koho Izuka, MD, STUDY_DIRECTOR, Coherus BioSciences
2026-02